Surrogate response biomarkers in prevention research: do they point the way or lead us astray?
Fabian
Carol J
CJ
D000328:Adult; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000473:pathology / Q000517:prevention & control*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000517:prevention & control; D018275:Carcinoma, Lobular / Q000517:prevention & control; D018450:Disease Progression; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008327:Mammography / Q000379:methods; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011237:Predictive Value of Tests; D017697:Premenopause; D012107:Research Design; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D017313:Fenretinide; D007334:Insulin-Like Growth Factor I